

Press release

SHL Telemedicine enters into Agreement with ChristianaCare for use of SmartHeart™ full 12 lead ECG technology

ChristianaCare, among the largest regional heart centers on the East Coast, to use SmartHeart™

Tel Aviv / Zurich, November 11, 2021 – SHL Telemedicine Ltd. today announced that it has entered into an agreement with ChristianaCare for the use of SmartHeart[™] Platform and Services. SHL will provide SmartHeart[™] 12 Lead ECG unit and technology for the delivery of ECGs and related services for use in certain clinical and patient care protocols.

Through this collaboration, ChristianaCare will deploy use of SmartHeart[™] FDA cleared 12 Lead ECG through its Center for Heart & Vascular Health for home telemonitoring of patients discharged following a heart attack, to help decrease general and cardiac emergency department presentation and hospital readmission rates.

"We are very pleased to enter into this collaboration with ChristianCare's Center for Heart & Vascular Health, which is among the largest, most capable regional heart centers on the East Coast of the US," said Erez Nachtomy, CEO of SHL Telemedicine. "SHL's unique FDA-approved and patented SmartHeart™ technology for performing full 12 Lead ECG will bring clinical benefits to patients of ChristianaCare as well as efficient use of its healthcare resource."

Further information

Elisabeth Wallimann, IRF, Phone: +41 43 244 81 41, shl@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.

About ChristianaCare

Headquartered in Wilmington, Delaware, <u>ChristianaCare</u> is one of the country's most dynamic health care organizations, centered on improving health outcomes, making high-quality care more accessible and lowering health care costs. ChristianaCare includes an extensive network of primary care and outpatient services, home health care, urgent care centers, three hospitals (1,299 beds), a freestanding



emergency department, a Level I trauma center and a Level III neonatal intensive care unit, a comprehensive stroke center and regional centers of excellence in heart and vascular care, cancer care and women's health. It also includes the pioneering Gene Editing Institute.

ChristianaCare is nationally recognized as a great place to work, rated by Forbes as the 5th best health system to work for in the United States and by IDG Computerworld as one of the nation's Best Places to Work in IT. ChristianaCare is rated by HealthGrades as one of America's 50 Best Hospitals and continually ranked among the nation's best by Newsweek and other national quality ratings. ChristianaCare is a nonprofit teaching health system with more than 260 residents and fellows. With its groundbreaking Center for Virtual Health and a focus on population health and value-based care, ChristianaCare is shaping the future of health care.